Samsung Biologics strikes a USD 330.8 Mn supply deal with AstraZeneca
Samsung Biologics announced the conclusion of a long-term supply deal with AstraZeneca worth USD 330.8 Million.
AZ has made several headlines the past few months, forming a slew of deals to manufacture and supply its products. Here, the company plans to leverage Samsung’s expertise in developing effective, novel biopharmaceuticals to expand its foothold in biologics manufacturing in the Asia Pacific region.
The deal struck shall help Asia Pacific countries to get better access to innovative healthcare services and augment Korea’s bio-health innovation. Samsung looks cheerf...
